SFX-01 and glioblastoma
Glioblastoma is a stage 4 malignant glioma representing 45% of all cases. Pre-clinical models show positive data for SFX-01 on tumour shrinkage and extended survival times.
Welcome to TheraCryf plc
Developing innovative therapeutics in oncology and behavioural brain disorders
TheraCryf plc is a clinical stage therapeutics company developing a new generation of innovative therapeutics in oncology and behavioural brain disorders. TheraCryf’s strategy is to generate compelling data sets with a goal of partnering its programmes with mid-size to large pharma.
Formerly Evgen Pharma plc, the Company acquired Chronos Therapeutics in April 2024. TheraCryf, the new name for the Group, reflects a wider mission and broader portfolio. The Company’s clinical asset is SFX-01, a patented sulforaphane-based medicine. Chronos’ neuropsychiatry assets use novel chemistry to address highly relevant targets in brain health and have composition of matter patent cover. The Group Company has the expertise to develop and commercialise the combined portfolio.
Our Pipeline
TheraCryf is focused on developing commercially successful products. We are currently targeting certain cancers and behavioural brain disorders.
Read more
NCE Ox-1 in Addiction and Anxiety Disorders
TheraCryf has a candidate stage antagonist molecule targeting the orexin 1 receptor with high specificity. This provides a potential treatment for addictive behaviours and anxiety.
NCE Atypical DAT inhibitor in Fatigue and Narcolepsy
The Company has a candidate stage atypical inhibitor of the brain dopamine transporter mechanism with potential utility in alleviating central fatigue and reducing the impact of the orphan condition narcolepsy.
Strategy
TheraCryf’s strategy is to demonstrate proof of concept for its proprietary drug candidates in carefully selected diseases and then conclude partnerships with larger organisations better positioned to take these drugs through large scale clinical trials and commercial launch.
Science
Clinical trials with TheraCryf's most advanced product, SFX-01, demonstrate objective responses in cancer patients.
Preclinical data has been generated for the orexin 1 receptor antagonist (Ox1) in preclinical models of addiction and for the DAT inhibitor in models of fatigue and narcolepsy.
Preclinical data has been generated for the orexin 1 receptor antagonist (Ox1) in preclinical models of addiction and for the DAT inhibitor in models of fatigue and narcolepsy.